Valuation dashboard for Alector, Inc. (ALEC) with P/E N/A, P/B -18.68, EV/EBITDA -1.95 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
Analysis Summary
Alector, Inc. reported revenue of $21.0M in the most recent fiscal year, growing at a 5-year CAGR of -0.1%.
Trailing-twelve-month margins: gross margin -360.9%, operating margin -9.1%, net margin -8.5%.
At the current price of $1.93, ALEC has negative trailing earnings (P/E not meaningful) and an ROE of -5.31%. Market capitalisation stands at $214M.
Balance sheet quality for ALEC: current ratio of 3.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -18.68 |
| EV / EBITDA | -1.95 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.18 |
| vs Current Price | -109.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ALEC | Alector, Inc. | $214M | -5.3% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.93 |
| Market Cap | $214M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -531.04% |
| Return on Invested Capital | -67.56% |
| Return on Assets | -58.10% |
| Gross Margin | -360.92% |
| Operating Margin | -914.56% |
| Net Margin | -850.13% |
Related companies: ABOS · APLT · CRBP · FATE · IRD · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ALEC: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks